Limits...
Correlation Between Clinical-Pathologic Factors and Long-Term Follow-Up in Young Breast Cancer Patients.

Zhao Y, Dong X, Li R, Song J, Zhang D - Transl Oncol (2015)

Bottom Line: Group 3 in risk factor grouping has the poorer prognosis than the other two groups.Patient age and axillary lymph nodes post-surgery are the independent and significant predictors of distant disease-free survival, local recurrence-free survival, and overall survival.The absence of PR relates to poor prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.

No MeSH data available.


Related in: MedlinePlus

ER, PR, and HER2 status with outcome. (A) ER, PR, and HER2 status in relation to LRFS by Kaplan-Meier survival analysis. Median survival time: level 1 with 83 months; level 2 with 46 months; level 3 with 37.5 months. (B) ER, PR, and HER2 status in relation to DDFS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 67 months; level 3 with 43 months. (C) ER, PR, and HER2 status in relation to OS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 89 months; level 3 with 70 months.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562982&req=5

f0015: ER, PR, and HER2 status with outcome. (A) ER, PR, and HER2 status in relation to LRFS by Kaplan-Meier survival analysis. Median survival time: level 1 with 83 months; level 2 with 46 months; level 3 with 37.5 months. (B) ER, PR, and HER2 status in relation to DDFS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 67 months; level 3 with 43 months. (C) ER, PR, and HER2 status in relation to OS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 89 months; level 3 with 70 months.

Mentions: Among the classification schemes evaluated, three levels of hormone receptor–positive breast cancer predicted LRFS, DDFS, and OS in our cohort (Figure 3, A–C, and Table 3). The level of ER, PR, and HER2 status was associated with LRFS (P < .0001, HR: 2.17, 95% CI: 1.58-2.98), DDFS (P < .0001, HR: 2.29, 95% CI: 1.84-4.23), and OS (P < .0001, HR: 2.95, 95% CI: 1.80-4.85). It identified the subset of carcinoma patients in young women with best prognosis (ER +, PR +, HER2 −), and it also identified the group of carcinoma patients who have the worst prognosis (ER + or PR +, HER2 −/+) in hormone receptor–positive breast cancer. The level of hormone receptor–positive breast cancer is a significant independent predictor of LRFS, DDFS, and OS.


Correlation Between Clinical-Pathologic Factors and Long-Term Follow-Up in Young Breast Cancer Patients.

Zhao Y, Dong X, Li R, Song J, Zhang D - Transl Oncol (2015)

ER, PR, and HER2 status with outcome. (A) ER, PR, and HER2 status in relation to LRFS by Kaplan-Meier survival analysis. Median survival time: level 1 with 83 months; level 2 with 46 months; level 3 with 37.5 months. (B) ER, PR, and HER2 status in relation to DDFS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 67 months; level 3 with 43 months. (C) ER, PR, and HER2 status in relation to OS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 89 months; level 3 with 70 months.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562982&req=5

f0015: ER, PR, and HER2 status with outcome. (A) ER, PR, and HER2 status in relation to LRFS by Kaplan-Meier survival analysis. Median survival time: level 1 with 83 months; level 2 with 46 months; level 3 with 37.5 months. (B) ER, PR, and HER2 status in relation to DDFS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 67 months; level 3 with 43 months. (C) ER, PR, and HER2 status in relation to OS by Kaplan-Meier survival analysis. Median survival time: level 1 with > 99 months; level 2 with 89 months; level 3 with 70 months.
Mentions: Among the classification schemes evaluated, three levels of hormone receptor–positive breast cancer predicted LRFS, DDFS, and OS in our cohort (Figure 3, A–C, and Table 3). The level of ER, PR, and HER2 status was associated with LRFS (P < .0001, HR: 2.17, 95% CI: 1.58-2.98), DDFS (P < .0001, HR: 2.29, 95% CI: 1.84-4.23), and OS (P < .0001, HR: 2.95, 95% CI: 1.80-4.85). It identified the subset of carcinoma patients in young women with best prognosis (ER +, PR +, HER2 −), and it also identified the group of carcinoma patients who have the worst prognosis (ER + or PR +, HER2 −/+) in hormone receptor–positive breast cancer. The level of hormone receptor–positive breast cancer is a significant independent predictor of LRFS, DDFS, and OS.

Bottom Line: Group 3 in risk factor grouping has the poorer prognosis than the other two groups.Patient age and axillary lymph nodes post-surgery are the independent and significant predictors of distant disease-free survival, local recurrence-free survival, and overall survival.The absence of PR relates to poor prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.

No MeSH data available.


Related in: MedlinePlus